Comparative Pharmacology
Head-to-head clinical analysis: AXUMIN versus SETHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXUMIN versus SETHOTOPE.
AXUMIN vs SETHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
1.0 mg IV every 12 hours for 7 days.
None Documented
None Documented
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical